TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of ...